← Leaderboards
Jack Thanh Nguyen
Adamas Pharmaceuticals, Inc.
$1,458,745
Attributed
$1,458,745
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $509.3K · FY2012–15$1M$750K$500K$250K$0
'12
'13
'14
'15
Funding mix
By agency
NIH$1,458,745 · 2
By mechanism
R33$992,576 · 1
R21$466,169 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroAntiviral AgentsAntiviral TherapyCell Culture TechniquesBaseClinically RelevantCategoriesCritical PathwaysDengueDoseDrug CombinationsCellsDrug DevelopmentDrug KineticsCostFda ApprovedFolic Acid AntagonistsGenerationsHepatitis CInfluenzaInfluenzavirusIntegration Host FactorsInvestigational New Drug ApplicationIn Vitro Activity
Grant awards (4)
Combinations of FDA-Approved Host-Targeted Drugs with Broad Antiviral Activity$483,247
R33 · FY2015 · AI · contact PI
Combinations of FDA-Approved Host-Targeted Drugs with Broad Antiviral Activity$509,329
R33 · FY2014 · AI · contact PI
Combinations of FDA-Approved Host-Targeted Drugs with Broad Antiviral Activity$128,625
R21 · FY2013 · AI · contact PI
Combinations of FDA-Approved Host-Targeted Drugs with Broad Antiviral Activity$337,544
R21 · FY2012 · AI · contact PI